// App-Quantinova.ai

901 : Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Researchers

Presenter

  • Sattva S. Neelapu

Principal Investigators

  • Fredrick B Hagemeister

  • Yasuhiro Oki

  • Linda Catherine Lacerte

  • Felipe Samaniego

  • Peter McLaughlin

  • Larry W. Kwak

  • Jorge E Romaguera

  • Michelle A. Fanale

  • Luis E Fayad

  • Robert Z. Orlowski

  • Michael Wang

  • Francesco Turturro

Medical Centers

  • Lymphoma/Myeloma Department, MD Anderson Cancer Center, Houston, TX

  • Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mucosa-associated lymphoid tissue lymphoma

  • Non-Hodgkin's Lymphoma

  • Follicular lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • single arm

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved